Discover

CLLS
Cellectis S.A.
2.89
2 x 2.81
1 x 2.89
bid
ask
+
0.13
4.71%
undefined @ 04:00 PM
2.89 +0.00 (0.00%)
Ytd-40.29%
1y9.06%
2.80
day range
2.90
2.35
52 week range
5.48
Open2.80Prev Close2.76Low2.80High2.90Mkt Cap290.21M
Vol17.13KAvg Vol32.12KEPS-0.67P/E-4.31Forward P/E-2.07
Beta3.20Short Ratio1.41Inst. Own16.65%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1150-d Avg2.95200-d Avg3.721yr Est6.67

CLLS News

Monthly information on share capital and company voting rights
globenewswire.com
Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of

Cellectis to Report Second Quarter Financial Results on August 6, 2026
globenewswire.com
Cellectis to Report Second Quarter Financial Results on August 6, 2026

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDA

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
globenewswire.com
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Offi

EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
globenewswire.com
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDA

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
globenewswire.com
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASD

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
globenewswire.com
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivot

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASD

Monthly information on share capital and company voting rights
globenewswire.com
Monthly information on share capital and company voting rights

PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Dat

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
globenewswire.com
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
globenewswire.com
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDA

Cellectis Reports Financial Results for the First Quarter 2026
globenewswire.com
Cellectis Reports Financial Results for the First Quarter 2026

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial)  Pivotal Phase 2 first interim analysis

Earnings Scheduled For May 11, 2026
benzinga.com
Earnings Scheduled For May 11, 2026

Monthly information on share capital and company voting rights
globenewswire.com
Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of

Cellectis to Report First Quarter Financial Results on May 11, 2026
globenewswire.com
Cellectis to Report First Quarter Financial Results on May 11, 2026

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
globenewswire.com
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT A

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NAS

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform
globenewswire.com
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS -

Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis
globenewswire.com
Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la p

NEW YORK, 13 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), société

Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
benzinga.com
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On M

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Monthly information on share capital and company voting rights
globenewswire.com
Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of

Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
seekingalpha.com
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript

Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
globenewswire.com
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NAS

Earnings Scheduled For March 19, 2026
benzinga.com
Earnings Scheduled For March 19, 2026

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sess

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Scheduled For November 7, 2025
benzinga.com
Earnings Scheduled For November 7, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Ses

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday&#39

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Sess

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Mo

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announce

benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com
Earnings Scheduled For August 4, 2025

benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com
Earnings Scheduled For May 12, 2025

benzinga.com
Earnings Scheduled For March 13, 2025

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Earnings Scheduled For November 6, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

benzinga.com
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday'

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that i

benzinga.com
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after

benzinga.com
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesd

Gainers

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 647 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  On Monday, 369 companies set new 52-week lows.

benzinga.com
Earnings Scheduled For August 3, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 199 companies reached new 52-week lows.

benzinga.com
Earnings Scheduled For May 4, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

benzinga.com
Earnings Scheduled For March 8, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn

benzinga.com
Earnings Scheduled For November 3, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's session, 402 companies made new 52-week lows.